The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism - PubMed (original) (raw)
The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism
B M Forman et al. Proc Natl Acad Sci U S A. 1997.
Abstract
LXRalpha is an orphan member of the nuclear hormone receptor superfamily that displays constitutive transcriptional activity. We reasoned that this activity may result from the production of an endogenous activator that is a component of intermediary metabolism. The use of metabolic inhibitors revealed that mevalonic acid biosynthesis is required for LXRalpha activity. Mevalonic acid is a common metabolite used by virtually all eukaryotic cells. It serves as a precursor to a large number of important molecules including farnesyl pyrophosphate, geranylgeranyl pyrophosphate, cholesterol, and oxysterols. Inhibition of LXRalpha could be reversed by addition of mevalonic acid and certain oxysterols but not by other products of mevalonic acid metabolism. Surprisingly, the constitutive activity of LXRalpha was inhibited by geranylgeraniol, a metabolite of mevalonic acid. These findings suggest that LXRalpha may represent a central component of a signaling pathway that is both positively and negatively regulated by multiple products of mevalonate metabolism.
Figures
Figure 1
The LXRα–RXR heterodimer displays constitutive activity. (A) Schematic diagram illustrating the amino acid sequence identity between FXR and LXRα. (B) The LXRα–RXR heterodimer is constitutively active in a cell-based transient transfection assay. CV-1 cells were transfected with the DR4x3 TK-Luc reporter and the indicated expression vectors. Luciferase and β-galactosidase activity were assayed 40 h posttransfection. (C) Constitutive activity is mediated by the LBDs of LXRα and RXR. Cells were transfected with the GAL4 reporter and vectors expressing the GAL4 DBD, the RXRα LBD, and the LBD of LXRα linked to the GAL4-DBD.
Figure 3
Activation of LXRα by-products of MVA metabolism. (A) Schematic illustration of the MVA biosynthetic pathway. (B) LXRα is activated by MVA and oxysterols. Cells were transfected as in Fig. 2 and then treated with 7.5 μM mevastatin in the presence of 200 μM MVA, isopentenol, or dimethylallylol; 50 μM geraniol, farnesol, or squalene; 25 μM lanosterol and Chol; 10 μM 20(S)-OH-Chol or 22(R)-OH-Chol. (C) Activation of LXRα by oxysterols. Cells were transfected with the DR4x3 reporter and an LXR expression vector and then treated with 10 μM of the indicated oxysterol or 100 nM LG268.
Figure 2
The constitutive activity of LXRα–RXR requires MVA biosynthesis. (A) Inhibition of constitutive activity by HMG–CoA reductase inhibitors. CV-1 cells were transfected as in Fig. 1_B_ and treated with 7.5 μM mevastatin, 7.5 μM lovastatin, or 200 μM MVA. (B) MVA is not required for the constitutive activity of Nurr1. Cells were transfected as indicated and then incubated with 7.5 μM mevastatin or 7.5 μM lovastatin. (C) Mevastatin does not inhibit ligand-dependent activation by nuclear hormone receptors. Cells were transfected with TK-Luc-based reporter constructs and receptor expression vectors and then treated with appropriate ligands (100 nM) as follows: CRBPII/hRXRα/LG268; SPP1x3/hVDR/1,25-di-OH-VD3; MLVx2/hTRβ/
l
-triiodothyronine and DR5x2/hRARα/Am580.
Figure 4
Geranylgeraniol inhibits the constitutive activity of LXRα-RXR. (A) Inhibition of LXRα–RXR by geranylgeraniol. (B) Geranylgeraniol does not inhibit the constitutive activity of Nurr1 or (C) ligand-dependent activation by nuclear receptors. Transient transfections were performed as above followed by exposure of cells to 30–50 μM geranylgeraniol.
Figure 5
Geranylgeranyl-PP inhibits the DNA binding activity of LXRα–RXR. (A) GG-PP inhibits the DNA binding activity of LXRα-RXR complexes. Mobility shift assays were performed as described with 1 μl of LXRα, 0.4 μl of hRXRa, or 1.4 μl of Nurr1 and 17.5 μM GG-PP. (B) Inhibition of DNA binding is specific to GG-PP. Mobility shift assays were performed as in Fig. 5_A_ with the following compounds: 25 μM of each prenyl-PP, 10 μM mevastatin, 200 μM MVA, or 50 μM of each prenyl alcohol.
Similar articles
- Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha.
Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP. Wang Y, et al. J Biol Chem. 2008 Sep 26;283(39):26332-9. doi: 10.1074/jbc.M804808200. Epub 2008 Aug 1. J Biol Chem. 2008. PMID: 18676367 Free PMC article. - Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis.
Jiang W, Miyamoto T, Kakizawa T, Nishio SI, Oiwa A, Takeda T, Suzuki S, Hashizume K. Jiang W, et al. Biochem Biophys Res Commun. 2006 Dec 8;351(1):176-84. doi: 10.1016/j.bbrc.2006.10.027. Epub 2006 Oct 19. Biochem Biophys Res Commun. 2006. PMID: 17054913 - Identification of human low-density lipoprotein receptor as a novel target gene regulated by liver X receptor alpha.
Ishimoto K, Tachibana K, Sumitomo M, Omote S, Hanano I, Yamasaki D, Watanabe Y, Tanaka T, Hamakubo T, Sakai J, Kodama T, Doi T. Ishimoto K, et al. FEBS Lett. 2006 Sep 4;580(20):4929-33. doi: 10.1016/j.febslet.2006.08.010. Epub 2006 Aug 14. FEBS Lett. 2006. PMID: 16920108 - Oxysterols, cholesterol homeostasis, and Alzheimer disease.
Vaya J, Schipper HM. Vaya J, et al. J Neurochem. 2007 Sep;102(6):1727-1737. doi: 10.1111/j.1471-4159.2007.04689.x. Epub 2007 Jun 15. J Neurochem. 2007. PMID: 17573819 Review. - Oxysterols in human circulation: which role do they have?
Björkhem I, Meaney S, Diczfalusy U. Björkhem I, et al. Curr Opin Lipidol. 2002 Jun;13(3):247-53. doi: 10.1097/00041433-200206000-00003. Curr Opin Lipidol. 2002. PMID: 12045393 Review.
Cited by
- Overview of Ursolic Acid Potential for the Treatment of Metabolic Disorders, Autoimmune Diseases, and Cancers via Nuclear Receptor Pathways.
Kadasah SF, Radwan MO. Kadasah SF, et al. Biomedicines. 2023 Oct 19;11(10):2845. doi: 10.3390/biomedicines11102845. Biomedicines. 2023. PMID: 37893218 Free PMC article. Review. - Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors.
Radwan MO, Kadasah SF, Aljubiri SM, Alrefaei AF, El-Maghrabey MH, El Hamd MA, Tateishi H, Otsuka M, Fujita M. Radwan MO, et al. Biomolecules. 2023 Sep 28;13(10):1465. doi: 10.3390/biom13101465. Biomolecules. 2023. PMID: 37892147 Free PMC article. Review. - HSD3B1 is an oxysterol 3β-hydroxysteroid dehydrogenase in human placenta.
Dickson A, Yutuc E, Thornton CA, Dunford JE, Oppermann U, Wang Y, Griffiths WJ. Dickson A, et al. Open Biol. 2023 May;13(5):220313. doi: 10.1098/rsob.220313. Epub 2023 May 3. Open Biol. 2023. PMID: 37132223 Free PMC article. - Identification of unusual oxysterols biosynthesised in human pregnancy by charge-tagging and liquid chromatography - mass spectrometry.
Dickson AL, Yutuc E, Thornton CA, Wang Y, Griffiths WJ. Dickson AL, et al. Front Endocrinol (Lausanne). 2022 Nov 10;13:1031013. doi: 10.3389/fendo.2022.1031013. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36440193 Free PMC article. - Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.
Chan ML, Shiu SW, Cheung CL, Yu-Hung Leung A, Tan KC. Chan ML, et al. Endocr Connect. 2022 Jun 15;11(6):e220019. doi: 10.1530/EC-22-0019. Endocr Connect. 2022. PMID: 35560019 Free PMC article.
References
- Mangelsdorf D J, Evans R M. Cell. 1995;83:841–50. - PubMed
- Forman B M, Tontonoz P, Chen J, Brun R P, Spiegelman B M, Evans R M. Cell. 1995;83:803–812. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources